OSE Immunotherapeutics provides an update on the first positive results and clinical development of CoVepiT, its multi-target T-cell anti-COVID vaccine
New clinical data confirm the good tolerance of CoVepiT and a very good level of T cell response in healthy... View Article
Valneva signs purchase agreement with European Commission for its inactivated COVID-19 vaccine VLA2001
Valneva, a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission... View Article
New member | Dopharma
DOPHARMA France is a veterinary pharmaceutical company, installed in Vair-sur-Loire (France, 44) for more than 50 years. Through its historical... View Article
Owkin becomes ‘unicorn’ with $180m investment from Sanofi and four new collaborative projects
Owkin and Sanofi are delighted to announce that Owkin is now a ‘unicorn’ – a startup valued at more than... View Article
OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
Clinical trial sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics.... View Article
World first: a double forearm transplant thanks to marina lugworms from the company Hemarina
Amrita Institute of Medical Sciences (AIMS) in Kochi, India, Becomes the First Hospital in the World to Carry Out Bilateral... View Article
Healthcare sovereignty is closely linked to industrial recovery!
The key issue of the Plan France 2030 centres on restoring French sovereignty in certain strategic areas in order to... View Article
Valneva wins approval from European Commission to supply Covid-19 vaccines
Valneva, a specialty vaccine company and member of Atlanpole Biotherapies, announced that the European Commission (“EC”) has approved an agreement... View Article
New member | AGS-M
AGS-M is a young CDMO dedicated to the development, the optimization and validation of manufacturing processes (production, clarification, purification and... View Article
Valneva raises €88 million
Valneva, a specialty vaccine company, announced today that the underwriters of its global offering of an aggregate of 4,500,000 new... View Article